![KAROLINSKA DEVELOPMENT AB [CBOE]](/cache/medias/logo_company/150x80-thumb/hkqPLGMQhBa8SkE.webp?v=1 "KAROLINSKA DEVELOPMENT AB [CBOE]"){kind=logo}
KAROLINSKA DEVELOPMENT AB [CBOE] news, videos and press releases
For more news please use our advanced search feature.
KAROLINSKA DEVELOPMENT AB [CBOE] - More news...
KAROLINSKA DEVELOPMENT AB [CBOE] - More news...
- Notice of Extraordinary General Meeting in Karolinska Development AB (publ)
- Karolinska Development divests its holding in the Danish dermatology company Henlez
- Karolinska Development’s portfolio company AnaCardio reports progress in two clinical trials with its drug candidate AC01
- Karolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of fracture rates in children with rare bone disease
- Karolinska Development’s portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG005
- Interim Report - January-June 2024
- Karolinska Development’s portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator
- Karolinska Development’s portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone
- Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection
- Karolinska Development invests in BOOST Pharma, expanding its portfolio
- Karolinska Development’s Annual General Meeting 2024
- Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC
- Interim Report - January-March 2024
- Notice of Annual General Meeting in Karolinska Development AB (publ)
- Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC
- Karolinska Development Annual Report 2023 published
- Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million
- Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units
- Karolinska Development’s portfolio company Umecrine Cognition presents preclinical Parkinson’s data on golexanolone at AD/PD
- Year-end Report - January-December 2023
- Karolinska Development’s portfolio company AnaCardio secures SEK 50 million as part of its Series A investment round
- Karolinska Development's portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product
- Karolinska Development's portfolio company OssDsign expects fourth-quarter revenues to exceed market estimates
- Karolinska Development’s portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration
- Karolinska Development’s portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis
- Karolinska Development’s portfolio company Umecrine Cognition raises additional funding for the clinical development of golexanolone
- Interim Report - January-September 2023
- Karolinska Development's portfolio company Modus Therapeutics raises capital to expand the development program for sevuparin
- Karolinska Development’s portfolio company PharmNovo reports positive results from a clinical phase 1 study of drug candidate PN6047
- Karolinska Development’s portfolio company PharmNovo reports promising preclinical results on abuse potential and withdrawal symptom relief for its candidate drug PN6047
